Aandeel ONWARD MEDICAL BRU:ONWD.BL, NL0015000HT4

quote:

Kaviaar schreef op 10 april 2024 12:51:

Stifel Initiates Research Coverage of ONWARD® Medical with
a Buy Rating and Target Price of EUR 12.00

EINDHOVEN, the Netherlands — April 9, 2024 — ONWARD Medical N.V. (Euronext: ONWD),
the medical technology company creating innovative therapies to restore movement, function,
and independence in people with spinal cord injury (SCI), today announced that Stifel, a US-
based full-service investment bank, has initiated coverage of ONWARD Medical with a Buy
rating and Target Price of EUR 12.00 per share. This is a premium of 140% to the closing price
of EUR 5.00 on April 8, 2024.

The initiation report was published April 8, 2024. Stifel joins four other banks whose analysts
cover ONWARD Medical, all of which maintain Buy ratings and Target Prices at substantial
premiums to the current share price.
“Stifel’s initiation of coverage reflects the value they place on the strategic positioning of our
brain-computer interface (BCI) platform as well as their strong confidence in our ability to
achieve this year’s milestones, which include the planned commercialization of our ARC-EX®
platform later this year,” said Dave Marver, CEO of ONWARD Medical. “Stifel is the largest
provider of global small-cap equity research, and we are gratified they recognize the value
ONWARD can create for investors in coming quarters.”
To learn more about ONWARD Medical’s commitment to partnering with the SCI community to
develop innovative solutions for restoring movement, function, and independence after spinal
cord injury, please visit ONWD.com.

*All ONWARD Medical devices and therapies, including but not limited to ARC-IM®, ARC-EX®, ARC-
BCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are
investigational and not available for commercial use.

quote:

Stork 49 schreef op 10 april 2024 16:08:

[...]
heel interessant maar we wisten het al; je hebt kennelijk iets gemist gisteren

quote:

Kaviaar schreef op 10 april 2024 16:14:

[...]

Goed nieuws kan men beter herhalen ;- )

quote:

Blik dekkende afbijt schreef op 16 april 2024 09:10:

Wanneer komen ze met je jaarcijfers?
Ik dacht deze week.
Die website van deze tent is de slechte die ik ooit in mijn leven ben tegengekomen.

quote:

Dagobert Duck schreef op 16 april 2024 12:40:

Onward behoort helaas wel weer bij de top drie van grootste dalers op de beurs vandaag!
En dat zonder enige reden.

quote:

Dagobert Duck schreef op 16 april 2024 12:40:

Onward behoort helaas wel weer bij de top drie van grootste dalers op de beurs vandaag!
En dat zonder enige reden.

quote:

Kaviaar schreef op 16 april 2024 17:38:

Krijgen we nog te zien welke grootaandeelhouders meegedaan hebben met de emissie?
Of hebben ze ervoor gezorgd dat het aantal gelijk gebleven is, door al bestaande aandelen te verkopen zodat hun belang gelijk blijft?

quote:

VBR schreef op 17 april 2024 09:05:

[...]

ir.onwd.com/static-files/6715816c-f96...

"Existing shareholders participated in the deal with an aggregate of 333,333 shares and 333,333
shares respectively allocated to INKEF Capital and EQT Life Sciences. Following the Offerings,
INKEF Capital and EQT Life Sciences will respectively hold 11.5% and 11.2% of the Company’s
share capital. An aggregate of 246,555 shares were also allocated to the following
management, founders, and members of the Board of Directors of the Company: Dave Marver,
CEO; Robert Odell, VP Operations; Lorenzo Fanti, VP Legal; Co-Founders Jocelyne Bloch and
Grégoire Courtine, CSO; and Directors Ian Curtis, Kristina Dziekan, and Fred Colen."